SHARE

As per the report published by Fior Markets, the global Alzheimer’s therapeutics market is expected to grow from USD 4.36 Billion in 2018 to USD 8.19 Billion by 2026, at a CAGR of 8.20% during the forecast period 2019-2026.Favorable reimbursement policies, well-developed healthcare facilities as well as high incidence of Alzheimer’s disease were some of the factors that led the North America region to dominate the global Alzheimer’s therapeutics market.

“Alzheimer’s Therapeutics Market by Drug Type (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonist, Others), Distribution Channel, Regions”,and Global Forecast 2019-2026.

DOWNLOAD FREE SAMPLE REPORT AT:https://www.fiormarkets.com/report-detail/396100/request-sample

Major players in the global Alzheimer’s therapeuticsmarket arePfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories,TevaPharmaceuticals Industries Ltd., Janssen Pharmaceutical, GE healthcare, Eli Lilly and Company, DiaGenic ASA, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca, and Daiichi Sankyo Company Ltd., among others. The companies are adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership to maintain their presence in the global alpha-amylase baking enzyme market. For instance in 2016, AC Immune announced its collaboration with Biogen for the development of protein ligands so as to target the proteins that are involved in the pathogenesis of neurological disorders.

Alzheimer’s disease is a neurodegenerative disorder that mostly occurs with old age and is one of the leading cause of dementia. Dementia exerts itself in the form of memory loss and other cognitive abilities serious enough to interfere with daily life.Alzheimer’s worsens over the time. Alzheimer’s is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer’s, individuals lose the ability to carry on a conversation and respond to their environment.

The global Alzheimer’s therapeutics market has been segmented on the basis of drug type, and distribution channel.The drug type segment is divided into cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonist and others. The others drug type segment consisting monoclonal antibodies and Tau targeting proteins are anticipated to grow at the highest CAGR of 10.29% over the forecast period. On the other hand,N-methyl-D-aspartate (NMDA) receptor antagonist segment dominated the global Alzheimer’s therapeutics market with a 54.38% share of market revenue in 2018.The use of the monoclonal antibodies for improving drugs for treating Alzheimer’s has increased. In addition, monoclonal antibodies are widely used in the diagnostic tests, analytic and chemical uses, therapeutic, and cancer treatment applications.The distribution channel segment includes hospital pharmacy, retail pharmacy and online sales. On account of increased patient hospitalization for the treatment of Alzheimer’s, the hospital pharmacy led the global Alzheimer’s therapeutics market with a 63.96% share of market revenue in 2018. The growing geriatric population dealing with weak immune system has widely increased the occurrence of the target diseases. The availability of large range of the medications for the detection of Alzheimer’s has increased the hospital pharmacy segment market share in the global Alzheimer’s therapeutics market.


Browse full report with TOC at:https://www.fiormarkets.com/report/alzheimer-s-therapeutics-market-by-drug-type-cholinesterase-inhibitors-396100.html

The factors such as the increasing prevalence of Alzheimer’s disease, introduction of new and innovative technologies and drugs as well as growing institutional support for research activities are driving the global Alzheimer’s therapeutics market. The high cost of treatment and stringent drug approval process are expected to restrain the market growth.  However, the use of artificial intelligence and cloud-based cognitive assessment systems in the research activities and robust drug pipeline will enhance the market size in the upcoming years.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.